The Mexican consensus on alcoholic hepatitis Velarde-Ruiz Velasco, J A; Higuera-de la Tijera, M F; Castro-Narro, G E ...
Revista de gastroenterologia de Mexico (English),
07/2020, Letnik:
85, Številka:
3
Conference Proceeding
The Mexican consensus on alcoholic hepatitis Velarde-Ruiz Velasco, J.A.; Higuera-de la Tijera, M.F.; Castro-Narro, G.E. ...
Revista de Gastroenterología de México (English Edition),
July-September 2020, 2020-07-00, 2020-07-01, Letnik:
85, Številka:
3
Journal Article
Recenzirano
Odprti dostop
Alcoholic hepatitis is a frequent condition in the Mexican population. It is characterized by acute-on-chronic liver failure, important systemic inflammatory response, and multiple organ failure. The ...severe variant of the disease implies elevated mortality. Therefore, the Asociación Mexicana de Gastroenterología and the Asociación Mexicana de Hepatología brought together a multidisciplinary team of health professionals to formulate the first Mexican consensus on alcoholic hepatitis, carried out utilizing the Delphi method and resulting in 37 recommendations. Alcohol-related liver disease covers a broad spectrum of pathologies that includes steatosis, steatohepatitis, different grades of fibrosis, and cirrhosis and its complications. Severe alcoholic hepatitis is defined by a modified Maddrey’s discriminant function score ≥ 32 or by a Model for End-Stage Liver Disease (MELD) score equal to or above 21. There is currently no specific biomarker for its diagnosis. Leukocytosis with neutrophilia, hyperbilirubinemia (>3 mg/dl), AST > 50 U/l (< 400 U/l), and an AST/ALT ratio > 1.5-2 can guide the diagnosis. Abstinence from alcohol, together with nutritional support, is the cornerstone of treatment. Steroids are indicated for severe disease and have been effective in reducing the 28-day mortality rate. At present, liver transplantation is the only life-saving option for patients that are nonresponders to steroids. Certain drugs, such as N-acetylcysteine, granulocyte-colony stimulating factor, and metadoxine, can be adjuvant therapies with a positive impact on patient survival.
La hepatitis alcohólica es una condición frecuente en población mexicana, se caracteriza por insuficiencia hepática aguda sobre crónica, importante reacción inflamatoria sistémica y fallo multiorgánico, que en la variante grave de la enfermedad implica una elevada mortalidad. Por lo anterior, la Asociación Mexicana de Gastroenterología y la Asociación Mexicana de Hepatología conjuntaron un equipo multidisciplinario de profesionales de la salud para elaborar el primer consenso mexicano de hepatitis alcohólica. El consenso fue elaborado con la metodología Delphi, emitiendo 37 recomendaciones. La enfermedad hepática relacionada al consumo de alcohol comprende un amplio espectro, que incluye esteatosis, esteatohepatitis, fibrosis en diferentes grados, cirrosis y sus complicaciones. La hepatitis alcohólica grave se define por una función modificada de Maddrey ≥32 o por un puntaje de MELD (Model for End-Stage Liver Disease) igual o mayor a 21. Actualmente no existe un biomarcador específico para el diagnóstico. La presencia de leucocitosis con neutrofilia, hiperbilirrubinemia (>3 mg/dL), AST > 50 U/L (<400 U/L), relación AST/ALT > 1.5-2 pueden orientar al diagnóstico. La piedra angular del tratamiento es la abstiencia junto con el soporte nutricional. Los esteroides estan indicados en la forma grave, en donde han resultado efectivos para reducir la mortalidad a 28 días. El trasplante hepático es en la actualidad la única opción con que se cuenta para salvar la vida de pacientes no respondedores a esteroides. Ciertos fármacos, como la N-acetilcisteína, el factor estimulante de colonias de granulocitos, y la metadoxina pueden ser una terapia adyuvante que puede impactar en la sobrevida de los pacientes.
Consenso Mexicano de hepatitis alcohólica Velarde-Ruiz Velasco, J.A.; Higuera-de la Tijera, M.F.; Castro-Narro, G.E. ...
Revista de gastroenterología de México,
July-September 2020, 2020-07-00, 2020-07-01, Letnik:
85, Številka:
3
Journal Article
Recenzirano
Odprti dostop
La hepatitis alcohólica es una condición frecuente en la población mexicana, se caracteriza por insuficiencia hepática aguda sobre crónica, importante reacción inflamatoria sistémica y fallo ...multiorgánico, que en la variante grave de la enfermedad implica una elevada mortalidad. Por lo anterior, la Asociación Mexicana de Gastroenterología y la Asociación Mexicana de Hepatología conjuntaron un equipo multidisciplinario de profesionales de la salud para elaborar el primer consenso mexicano de hepatitis alcohólica. El consenso fue elaborado con la metodología Delphi, emitiendo 37 recomendaciones. La enfermedad hepática relacionada con el consumo de alcohol comprende un amplio espectro, que incluye esteatosis, esteatohepatitis, fibrosis en diferentes grados, cirrosis y sus complicaciones. La hepatitis alcohólica grave se define por una función modificada de Maddrey ≥ 32 o por un puntaje de MELD (Model for End-Stage Liver Disease) igual o mayor a 21. Actualmente no existe un biomarcador específico para el diagnóstico. La presencia de leucocitosis con neutrofilia, hiperbilirrubinemia (> 3 mg/dL), AST > 50 U/L (< 400 U/L), relación AST/ALT > 1.5-2 pueden orientar al diagnóstico. La piedra angular del tratamiento es la abstiencia junto con el soporte nutricional. Los esteroides estan indicados en la forma grave, en donde han resultado efectivos para reducir la mortalidad a 28 días. El trasplante hepático es en la actualidad la única opción con que se cuenta para salvar la vida de pacientes que no responden a los esteroides. Ciertos fármacos, como la N-acetilcisteína, el factor estimulante de colonias de granulocitos y la metadoxina, pueden ser una terapia adyuvante que puede mejorar la supervivencia de los pacientes.
Alcoholic hepatitis is a frequent condition in the Mexican population. It is characterized by acute-on-chronic liver failure, important systemic inflammatory response, and multiple organ failure. The severe variant of the disease implies elevated mortality. Therefore, the Asociación Mexicana de Gastroenterología and the Asociación Mexicana de Hepatología brought together a multidisciplinary team of health professionals to formulate the first Mexican consensus on alcoholic hepatitis, carried out utilizing the Delphi method and resulting in 37 recommendations. Alcohol-related liver disease covers a broad spectrum of pathologies that includes steatosis, steatohepatitis, different grades of fibrosis, and cirrhosis and its complications. Severe alcoholic hepatitis is defined by a modified Maddrey's discriminant function score ≥ 32 or by a Model for End-Stage Liver Disease (MELD) score equal to or above 21. There is currently no specific biomarker for its diagnosis. Leukocytosis with neutrophilia, hyperbilirubinemia (> 3 mg/dL), AST > 50 U/l (< 400 U/l), and an AST/ALT ratio > 1.5-2 can guide the diagnosis. Abstinence from alcohol, together with nutritional support, is the cornerstone of treatment. Steroids are indicated for severe disease and have been effective in reducing the 28-day mortality rate. At present, liver transplantation is the only life-saving option for patients that are nonresponders to steroids. Certain drugs, such as N-acetylcysteine, granulocyte-colony stimulating factor, and metadoxine, can be adjuvant therapies with a positive impact on patient survival.
Conventional catheter-based esophageal pH monitoring system produce discomfort and interference with normal activities and diet. An alternative is the wireless pH system which is more comfortable and ...offers extended recording periods.
To know the performance, the clinical utility and tolerability of wireless pH 48 h-monitoring system.
Forty-one consecutive patients were randomized for conventional or wireless pH-testing. Successful placement of monitoring devices and data collection were evaluated. Frequency of pathologic gastroesophageal reflux was registred with both methods. A questionnaire was applied in all the cases to know the frequency of discomfort, interference with normal activities and diet related to the study.
Conventional catheter-based pH-testing was performed in 21 patients and wireless system in 20. Successful placement of pH capsule was achieved in 20 of 22 patients and 48-h pH studies were completed in all of them. Pathologic gastroesophageal reflux was more frequently detected in the wireless system group (15 vs. 9 patients, p = NS). Ambulatory esophageal pH testing was well tolerated with both techniques. Chest discomfort was more frequently observed in the wireless group (11 vs. 2 patients, p = 0.005, RM 11.6, IC 95% 2.1-63.7).
Ambulatory pH-monitoring wireless system is an efficient and well tolerated method which could detect a high proportion of subjects with pathologic reflux in comparison with conventional system.
Endoscopic-negative reflux disease (ENRD) is a heterogeneous population. There are few data regarding the prevalenece of each group and subgroups that constitutes ENRD population.
To describe the ...prevalence of the differents groups and subgroups in ENRD.
We studied consecutive patients with frequent heartburn and acid regurgitation with endoscopically normal esophageal mucosa in whom ambulatory 24-h esophageal pH monitoring was performed. According with the pH-testing data and the correlation between symptoms and the acid reflux events, the subjects were classified in two groups: non-erosive gastroesophageal reflux disease (NERD) and functional heartburn. The functional heartburn group was splited in 3 subgroups: asymptomatics during pH-monitoring, hipersensitive esophagus and those with physiologic reflux with negative association between symptoms and acid reflux events. These last subgroup was classified in: minute changes of intra-esophegeal pH (upper than 4, n = 19) and non-acid related stimuli.
One hundred and eleven patients with ENRD were classified in NERD (28%, n = 31) and functional heartburn (72%, n = 80). Patients with functional heartburn were classified in asymptomatics during pH-monitoring (11%, n = 12), hipersensitive esophagus (9%, n = 10) and those with physiologic reflux with negative association between symptoms and acid reflux events (52%, n = 58). In these last subgroup 19 (17%) patients were classified as minute changes of intra-esophegeal pH (upper than 4) and 39 (35%) as non-acid related stimuli.
Even most of the patients with ENRD have normal ambulatory pH-test, their symptoms are related with drops of esophageal pH in 26% of the cases. Eleven percent do not have symptoms during ambulatory pH-monitoring.
PDF
